According to Taro Pharmaceutical's latest financial reports the company's current EPS (TTM) is โน105.71. an increase over its 2022 EPS that were of โน105.71.
Year | EPS | Change |
---|---|---|
2023 | โน105.71 | 0% |
2022 | โน105.71 | 2950% |
2021 | โน3.47 | -100.51% |
2020 | -โน685.39 | -222.45% |
2019 | โน559.75 | -18.02% |
2018 | โน682.79 | 53.01% |
2017 | โน446.24 | -55.95% |
2016 | โน1,013 | -13.41% |
2015 | โน1,170 | 36.92% |
2014 | โน854.36 | 37.71% |
2013 | โน620.41 | 21.15% |
2012 | โน512.10 | 44.15% |
2011 | โน355.26 |
Company | EPS | EPS differencediff. | Country |
---|---|---|---|
![]() Pfizer PFE | โน120.44 | 13.93% | ๐บ๐ธ USA |
![]() Merck MRK | โน597.65 | 465.36% | ๐บ๐ธ USA |
![]() Johnson & Johnson JNJ | โน785.70 | 643.25% | ๐บ๐ธ USA |
![]() Teva Pharmaceutical Industries TEVA | -โน98.78 | -193.44% | ๐ฎ๐ฑ Israel |
![]() GlaxoSmithKline GSK | โน135.15 | 27.85% | ๐ฌ๐ง UK |
![]() Novartis NVS | โน557.15 | 427.05% | ๐จ๐ญ Switzerland |